- Home
- DSS vs VRAX Comparison
DSS vs VRAX Comparison
Compare DSS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- VRAX
- Stock Information
- Founded
- DSS 1984
- VRAX 2013
- Country
- DSS United States
- VRAX United Kingdom
- Employees
- DSS N/A
- VRAX N/A
- Industry
- DSS Containers/Packaging
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DSS Consumer Discretionary
- VRAX Health Care
- Exchange
- DSS Nasdaq
- VRAX Nasdaq
- Market Cap
- DSS 7.3M
- VRAX 7.8M
- IPO Year
- DSS N/A
- VRAX 2022
- Fundamental
- Price
- DSS $0.87
- VRAX $1.92
- Analyst Decision
- DSS
- VRAX
- Analyst Count
- DSS 0
- VRAX 0
- Target Price
- DSS N/A
- VRAX N/A
- AVG Volume (30 Days)
- DSS 64.7K
- VRAX 376.6K
- Earning Date
- DSS 11-13-2024
- VRAX 02-05-2025
- Dividend Yield
- DSS N/A
- VRAX N/A
- EPS Growth
- DSS N/A
- VRAX N/A
- EPS
- DSS N/A
- VRAX N/A
- Revenue
- DSS $25,019,000.00
- VRAX $84,872.00
- Revenue This Year
- DSS N/A
- VRAX $5,169.18
- Revenue Next Year
- DSS N/A
- VRAX $66.97
- P/E Ratio
- DSS N/A
- VRAX N/A
- Revenue Growth
- DSS N/A
- VRAX 7.03
- 52 Week Low
- DSS $0.81
- VRAX $0.60
- 52 Week High
- DSS $3.08
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- DSS 38.70
- VRAX 51.17
- Support Level
- DSS $0.81
- VRAX $1.51
- Resistance Level
- DSS $0.97
- VRAX $2.38
- Average True Range (ATR)
- DSS 0.09
- VRAX 0.24
- MACD
- DSS -0.00
- VRAX 0.03
- Stochastic Oscillator
- DSS 15.69
- VRAX 46.88
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.